Nucala Disease Interactions

There have been reports of serious infections, including infections with opportunistic pathogens, and reactivation of latent infections in patients receiving interleukin inhibitors. Treatment with these agents should not be initiated in patients with an active infection until the infection resolves or is adequately treated. Caution is recommended when considering the use of interleukin inhibitors in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.

Population pharmacokinetic analyses suggest that mepolizumab clearance was comparable between subjects with creatinine clearance values between 50 and 80 mL/min and patients with normal renal function. There is limited data available in subjects with creatinine clearance values less than 50 mL/min. Caution is recommended if using this agent in these patients. Clinical monitoring of renal function is recommended.